Increasing trend of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of Northern India

Microbial Drug Resistance

Volumn 21, Issue 5, 2015, Pages 545-550

  Singh, Avinash ^a,b   Prasad, Kashi Nath ^a   Misra, Richa ^a   Rahman, Mohibur ^a   Singh, Satyendra Kumar ^a   Rai, Ravi Prakash ^a   Tripathi, Aparna ^a   Srivastava, Janmejai Kumar ^b  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b AMITY UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; VANCOMYCIN; ANTIINFECTIVE AGENT; DAPTOMYCIN;

AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; EPSILOMETER TEST; INDIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; TERTIARY CARE CENTER; TRANSMISSION ELECTRON MICROSCOPY; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; ANTIBIOTIC RESISTANCE; BIOFILM; CELL WALL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RETROSPECTIVE STUDY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; ULTRASTRUCTURE;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOFILMS; CELL WALL; DAPTOMYCIN; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, TRANSMISSION; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TERTIARY CARE CENTERS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84943275775     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2015.0004     Document Type: Article

References (31)

1. Appelbaum, P.C. 2007. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30:398-408.
2. Ariza, J., M. Pujol, J. Cabo, C. Pena, N. Fernandez, J. Linares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588.
3. Campanile, F., D. Bongiorno, M. Falcone, F. Vailati, M.B. Pasticci, M. Perez, A. Raglio, F. Rumpianesi, C. Scuderi, F. Suter, et al. 2012. Changing Italian nosocomial-community trends and heteroresistance in Staphylococcus aureus from bacteremia and endocarditis. Eur. J. Clin. Microbiol. Infect. Dis. 31:739-745.
4. Campanile, F., S. Borbone, M. Perez, D. Bongiorno, V. Cafiso, T. Bertuccio, S. Purrello, D. Nicolosi, C. Scuderi, and S. Stefani. 2010. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates. Int. J. Antimicrob. Agents 36:415-419.
5. Cui, L., E. Tominaga, H.M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 1079-1082.
6. Fassel, T.A., P.E. Mozdziak, J.R. Sanger, and C.E. Edmiston. 1997. Paraformaldehyde effect on ruthenium red and lysine preservation and staining of the staphylococcal glycocalyx. Microsc. Res. Tech. 36:422-427.
7. Fink, S.L, R.A. Martinello, S.M. Campbell, and T.S. Murray. 2012. Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans. Antimicrob. Agents Chemother. 56: 582-583.
8. Ganguly, N.K., N.K. Arora, S.J. Chandy, M.N. Fairoze, J.P. Gill, U. Gupta, S. Hossain, S. Joglekar, P.C. Joshi, M. Kakkar, et al. 2011. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J. Med. Res. 134:281-294.
9. Harigaya, Y., D. Ngo, A.J. Lesse, V. Huang, and B.T. Tsuji. 2011. Characterization of heterogeneous vancomycinintermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphylococcus aureus. BMC Infect. Dis. 11:287.
10. Heilmann, C., O. Schweitzer, C. Gerke, N. Vanittanakom, D. Mack, and F. Gotz. 1996. Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis. Mol. Microbiol. 20:1083-1091.
11. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
12. Howden, B.P., J.K. Davies, P.D. Johnson, T.P. Stinear, and M.L. Grayson. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycinintermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
13. Howden, B.P., P.D. Johnson, P.B. Ward, T.P. Stinear, and J.K. Davies. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50:3039-3047.
14. Howden, B.P., P.B. Ward, P.G. Charles, T.M. Korman, A. Fuller, P. du Cros, E.A. Grabsch, S.A. Roberts, J. Robson, K. Read, et al. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528.
15. Hussain, F.M, S. Boyle-Vavra, P.B. Shete, and R.S. Daum. 2002. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J. Infect. Dis. 186:661-667.
16. Kelley, P.G., W. Gao, P.B. Ward, and B.P. Howden. 2011. Daptomycin non-susceptibility in vancomycinintermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J. Antimicrob. Chemother. 66:1057-1060.
17. Maor, Y., M. Hagin, N. Belausov, N. Keller, D. Ben-David, and G. Rahav. 2009. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619-624.
18. Maor, Y., G. Rahav, N. Belausov, D. Ben-David, G. Smollan, and N. Keller. 2007. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J. Clin. Microbiol. 45:1511-1514.
19. Mirani, Z.A., M. Aziz, M.N. Khan, I. Lal, N.U. Hassan, and S.I. Khan. 2013. Biofilm formation and dispersal of Staphylococcus aureus under the influence of oxacillin. Microb. Pathog. 61-62:66-72.
20. Organization, W.H. 2011. World Health Statistics. World Health Organization, France.
21. Pereira, P.M., S.R. Filipe, A. Tomasz, and M.G. Pinho. 2007. Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 51:3627-3633.
22. Plipat, N., G. Livni, H. Bertram, and R.B. Thomson, Jr. 2005. Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:2494-2496.
23. Richter, S.S., S.W. Satola, E.K. Crispell, K.P. Heilmann, C.L. Dohrn, F. Riahi, A.J. Costello, D.J. Diekema, and G.V. Doern. 2011. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States. J. Clin. Microbiol. 49: 4203-4207.
24. Rybak, M.J., S.N. Leonard, K.L. Rossi, C.M. Cheung, H.S. Sader, and R.N. Jones. 2008. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46:2950-2954.
25. Sakoulas, G., G.M. Eliopoulos, R.C. Moellering, Jr, R.P. Novick, L. Venkataraman, C. Wennersten, P.C. De-Girolami, M.J. Schwaber, and H.S. Gold. 2003. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediatelevel glycopeptide resistance? J. Infect. Dis. 187:929-938.
26. Sakoulas, G., P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellering, Jr, and G.M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
27. Song, J.H., K. Hiramatsu, J.Y. Suh, K.S. Ko, T. Ito, M. Kapi, S. Kiem, Y.S. Kim, W.S. Oh, K.R. Peck, et al. 2004. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 48:4926-4928.
28. Soriano, A., F. Marco, J.A. Martinez, E. Pisos, M. Almela, V.P. Dimova, D. Alamo, M. Ortega, J. Lopez, and J. Mensa. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
29. Vuong, C., H.L. Saenz, F. Gotz, and M. Otto. 2000. Impact of the agr quorum-sensing system on adherence to polystyrene in Staphylococcus aureus. J. Infect. Dis. 182: 1688-1693.
30. Wong, S.S., P.L. Ho, P.C. Woo, and K.Y. Yuen. 1999. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin. Infect. Dis. 29:760-767.
31. Wootton, M., R.A. Howe, R. Hillman, T.R. Walsh, P.M. Bennett, and A.P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect heteroresistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.